Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer is a phase 3, randomised interventional study registered as NCT05086614 by Fudan University, with a registry enrolment figure of 2500 participants, started 2021-04-01 and due to reach its primary completion in 2027-03-31. Interventions recorded: Thymosin Alpha1. Conditions listed: Stage II Colorectal Cancer; Stage III Colorectal Cancer. Primary outcome: 3-year disease-free survival rate. Colorectal eligibility wording from the registry: "* Colorectal cancer receiving radical resection". Sites: China. No results are recorded here; the registry entry is the source.